Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. Oppenheimer lowered their price objective on shares of Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a report on Wednesday, June 12th. JMP Securities restated a market outperform rating and set a $6.00 price objective on shares of Cellectis in a report on Friday, May 31st.

Cellectis Stock Performance

CLLS opened at $1.88 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.69. The company’s fifty day moving average price is $2.58 and its two-hundred day moving average price is $2.73. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The company has a market cap of $104.49 million, a price-to-earnings ratio of -1.46 and a beta of 3.11.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. The business had revenue of $6.50 million for the quarter. On average, analysts expect that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Trading of Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. boosted its stake in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 424,533 shares of the biotechnology company’s stock after buying an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned approximately 0.76% of Cellectis worth $1,125,000 as of its most recent SEC filing. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.